• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • Microbiology and Immunology
    • View Item
    •   ScholarShip Home
    • Division of Health Sciences
    • Brody School of Medicine
    • Microbiology and Immunology
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia

    Thumbnail
    View/ Open
    oncotarget-06-6597.PMC4466637.pdf (4.642Mb)

    Show full item record
    Author
    Cani, Alice; Simioni, Carolina; Martelli, Alberto M.; Zauli, Giorgio; Tabellini, Giovanna; Ultimo, Simona; McCubrey, James A.; Capitani, Silvano; Neri, Luca M.
    Abstract
    T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive neoplastic disorder in which chemotherapy resistance and refractory relapses occur, with a poorer prognostic outcome. Constitutively active PI3K/Akt/mTOR pathway is a common feature of T-ALL upregulating cell proliferation, survival and drug resistance. This pathway is currently under clinical trials with small molecules inhibitors (SMI). To verify whether a multi-inhibition treatment against Akt protein could enhance the efficacy of individual drug administration and overcome drug resistance as well as to obtain a decrease in single drug concentration, we tested on T-ALL cell lines the effects of combined treatments with three Akt inhibitors with different mode of action, GSK690693, MK-2206 and Perifosine. In cells with hyperactivated Akt, combined administration of the drugs displayed a significant synergistic and cytotoxic effect and affected PI3K/Akt/mTOR pathway at much lower concentration than single drug use. Highest synergistic effect for full inhibition of Akt was also related to the timing of every drug administration. Furthermore the triple treatment had greater efficacy in inducing cell cycle arrest in G0/G1 phase and both apoptosis and autophagy. Targeting Akt as a key protein of PI3K/Akt/mTOR pathway with multiple drugs might represent a new and promising pharmacological strategy for treatment of T-ALL patients.
    URI
    http://hdl.handle.net/10342/5593
    Subject
     T-acute lymphoblastic leukemia; Akt; Perifosine; GSK690693; MK-2206 
    Date
    2015-03
    Citation:
    APA:
    Cani, Alice, & Simioni, Carolina, & Martelli, Alberto M., & Zauli, Giorgio, & Tabellini, Giovanna, & Ultimo, Simona, & McCubrey, James A., & Capitani, Silvano, & Neri, Luca M.. (March 2015). Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget, (6:9), p.6597-6610. Retrieved from http://hdl.handle.net/10342/5593

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Cani, Alice, and Simioni, Carolina, and Martelli, Alberto M., and Zauli, Giorgio, and Tabellini, Giovanna, and Ultimo, Simona, and McCubrey, James A., and Capitani, Silvano, and Neri, Luca M.. "Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia". Oncotarget. 6:9. (6597-6610.), March 2015. August 16, 2022. http://hdl.handle.net/10342/5593.
    Chicago:
    Cani, Alice and Simioni, Carolina and Martelli, Alberto M. and Zauli, Giorgio and Tabellini, Giovanna and Ultimo, Simona and McCubrey, James A. and Capitani, Silvano and Neri, Luca M., "Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia," Oncotarget 6, no. 9 (March 2015), http://hdl.handle.net/10342/5593 (accessed August 16, 2022).
    AMA:
    Cani, Alice, Simioni, Carolina, Martelli, Alberto M., Zauli, Giorgio, Tabellini, Giovanna, Ultimo, Simona, McCubrey, James A., Capitani, Silvano, Neri, Luca M.. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget. March 2015; 6(9) 6597-6610. http://hdl.handle.net/10342/5593. Accessed August 16, 2022.
    Collections
    • Microbiology and Immunology

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback